Form Type:  6-K
Filing Date:  5/16/2018 
CIK:  0001674988 
Address:  SMEDELAND 36
City, State, Zip:  COPENHAGEN,  00000 
Telephone:  (458) 877-3600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.13 (-0.72%)  
Trade Time: 
Mar 22  
Market Cap: 
Trade ZEAL now with

© 2019  
Description of Business
We were founded in 1998 and are a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. Our current pipeline of internal product candidates focuses on specialty gastrointestinal and metabolic diseases. Our portfolio also includes two clinical license collaborations with Boehringer Ingelheim. Since 2003 we have had a license collaboration with Sanofi, or the Sanofi License Agreement, in the diabetes field pertaining to the development and commercialization of lixisenatide, both as a standalone therapy and as a combination therapy. Pursuant to the Sanofi License Agreement, we were entitled to receive certain royalties and commercial milestones in respect of global net-sales of Soliqua® 100/33/ Suliqua® and Lyxumia®/Adlyxin® .
Register and access this filing in:     
  FORM 6-K
  EXHIBIT 99.1
    Note 1 - Significant accounting policies and significant ...
  EXHIBIT 99.2